

SUPPLEMENTARY APPENDIX

Table of Contents

Supplementary Methods..... 2

Supplementary Figures..... 2

 Supplementary Figure 1..... 2

 Supplementary Figure 2..... 3

 Supplementary Figure 3..... 4

 Supplementary Figure 4..... 5

 Supplementary Figure 5..... 6

Supplementary Tables..... 6

 Supplementary Table 1..... 6

 Supplementary Table 2..... 7

 Supplementary Table 3..... 7

 Supplementary Table 4..... 7

 Supplementary Table 5..... 7


 Supplementary Table 6..... 8

Supplementary Methods


Proteome-wide phage display

We adapted a previously published protocol for phage immunoprecipitation sequencing (PhIP-Seq).^{1,2,3} A library containing 731,724 49–amino acid peptides with 25–amino acid overlaps was cloned into T7 bacteriophage. Patient CSF was incubated with 10^{10} plaque-forming units of the phage library, antibodies were immunoprecipitated with protein A/G magnetic beads, and antibody-bound phage was amplified in *Escherichia coli* before a second round of immunoprecipitation. Enriched phage lysates were adaptor-ligated and barcoded before pair-end sequencing on an Illumina NovaSeq to a depth of 2 million reads per sample. Reads were trimmed, aligned at the amino acid level using RAPSearch, and normalized to sequencing depth to generate reads per 100,000 (RPK) for each sample. Enriched peptides were identified by calculating the fold change (FC) of normalized counts between samples immunoprecipitated with CSF versus magnetic beads only. Z-scores were calculated for each IM case using all OND controls as a reference and for each OND control using all other OND controls as a reference. Autoantibody “hits” were selected using criteria adapted from a previously published methodology⁴: 1) Z-score > 2 in at least 10% of cases, 2) Z-score > 2 in 0 controls, and 3) FC > 50 in at least 2 cases. A step-by-step protocol is available at www.protocols.io/view/scaled-moderate-throughput-multichannel-hip-8epv5zp6dv1b/v1.


Supplementary Figures




Supplementary Figure 1. (A) Flow chart summarizing the selection of the discovery cohort. The initial discovery cohort comprised 16 patients with IM. The extended discovery cohort added 16 more patients with IM using the same selection criteria.




Supplementary Figure 2. (A) Epitope mapping of anti-CD320 autoantibodies in IM cases. All anti-CD320 positive IM cases enriched the same region in the extracellular domain (ECD, blue) of CD320. (B) Standard curve of the epitope-specific Luminex-based immunoassay using a patient-derived monoclonal anti-CD320 antibody. The MFI fold change represents autoantibody enrichment for the antigenic peptide of CD320 conjugated to bovine serum albumin (BSA) versus enrichment for BSA alone. Fitting with an asymmetric sigmoidal 5-parameter logistic curve is shown in blue. (C) Representative immunofluorescent images of a cell-based assay using a patient-derived monoclonal anti-CD320 antibody. Compared to mock transfected HEK293T cells (column 1), HEK293T cells transfected with FLAG-tagged CD320 (columns 2-6) demonstrate strong overlap (bottom row) between FLAG signal (red, top row) and human IgG signal (green, middle row) across a range of antibody concentrations. (D) Correlation between CSF holoTC concentration and CSF MMA concentration in OND controls (left), chronic/subacute anti-CD320 negative IM cases (middle), or chronic/subacute anti-CD320 positive IM cases (right). Time course is defined as acute (<1 month), subacute (1 month – 6 months), or chronic (>6 months).



Supplementary Figure 3. Representative MRI findings in Case 25 (A), Case 29 (B), Case 32 (C), Case 26 (D), Case 27 (E), and Case 30 (F), demonstrating dorsal and or lateral T2 hyperintensities in the cervical spine and/or thoracic spine.



Supplementary Figure 4. (A) Flow chart summarizing the selection of validation cohort 1. **(B)** Correlation between serum and CSF anti-CD320 MFI fold change in paired samples from validation cohort 1 ($n=38$, $P < 0.0001$, Pearson correlation). **(C)** Anti-CD320 concentration (interpolated and corrected for dilution factor) in paired serum (red) and CSF (blue) samples. Paired samples are connected by a black line. **(D)** Correlation between anti-CD320 MFI fold change and the CSF/serum holoTC ratio, a proxy for B12 transport from the blood to CNS. Both serum (red, $r = -0.248$, Pearson correlation coefficient) and CSF (blue, $r = -0.24$, Pearson correlation coefficient) anti-CD320 MFI fold changes are negatively correlated with B12 transport. **(E)** Longitudinal anti-CD320 signal in 9 IM cases from Validation Cohort 1.



Supplementary Figure 5. (A) Anti-CD320 MFI fold change (left y-axis) and seropositive rate (right y-axis) in anti-AQP4+ myelopathy (brown), anti-MOG+ myelopathy (blue), and IM (purple) cases from validation cohort 2.

Supplementary Tables

Antigen	Subcellular Localization	Tissue Specificity
AOAH	secreted	Lymphoid tissue - Immune response
ASAH2	intracellular	Small intestine - Absorption
BPIFB4	secreted	Pituitary gland - Hormone signaling
C19ORF57	intracellular	Testis - Spermatogenesis
CD320	membrane	Brain - Mitochondrial translation
DUSP12	intracellular	Non-specific - Transcription
FZD5	membrane	Liver & Intestine - Lipid metabolism
GIMAP1	membrane	Lymphoid tissue - Immune response
GIPC3	intracellular	Retina & Testis - Cilium
KCNRG	intracellular	Fallopian tube - Tissue development
LPPR3	membrane	Brain - Neuronal signaling
NFKBIB	intracellular	Testis - Spermatogenesis
OR3A2	intracellular membrane	Brain - Olfactory receptor
PTPRU	membrane	Non-specific - Unknown function
QTRT1	intracellular	Non-specific - Protein processing
SFXN5	intracellular	Brain - Neuronal signaling
SPRTN	intracellular	Testis - Basic cellular processes
XPO7	intracellular membrane	Non-specific - Transcription
ZNF618	intracellular	Thyroid gland - Unknown function

Supplementary Table 1. Summary of PhIP-seq hits enriched in IM. Most hits demonstrate intracellular localization or non-CNS tissue specificity based on data from the Human Protein Atlas RNA-seq expression data. CD320, LPPR3, and OR3A2 were the only hits with membrane localization and brain specificity. We focused on CD320 because autoantibodies targeting this antigen were previously reported in a case of IM.

	OND	IM
No. of patients	32	32
Age (range)	35 (19-54)	54 (26-80)
Sex (%)		
Female	21 (66)	13 (41)
Male	11 (34)	19 (59)

Supplementary Table 2. Comparison of OND controls and IM cases in discovery cohort.

Removed per MedRxiv policy regarding detailed description of comorbidities.

Supplementary Table 3. Clinical summaries of the discovery cohort. Anti-CD320 positive cases are highlighted in red. Serum B12 was borderline low (280) in Case 24 but with normal homocysteine and MMA. Serum B12 was normal (404) on initial presentation in Case 27 and borderline low (249) on second presentation then repleted (1378).

	Discovery Cohort	Validation Cohort 1	Validation Cohort 2
No. of patients	32	94	25
Age (range)	54 (26-80)	46 (18-78)	58 (31-76)
Sex (%)			
Female	13 (41)	52 (55)	9 (36)
Male	19 (59)	42 (45)	16 (64)
Anti-CD320 (%)			
Negative	14 (44)	51 (54)	13 (52)
Positive	18 (56)	43 (46)	12 (48)

Supplementary Table 4. Comparison of discovery and validation cohorts.

Validation Cohort 1	Anti-CD320 negative	Anti-CD320 positive	P-value
No. of patients (%)	51 (54)	43 (46)	
Age (range)	46 (18-78)	45 (20-71)	0.624
Sex (%)			0.680
Female	27 (53)	25 (58)	
Male	24 (47)	18 (42)	
CSF findings (%)			0.347
Normal	21 (48)	19 (61)	
Inflammatory	23 (52)	12 (39)	

Supplementary Table 5. Comparison of anti-CD320 negative and positive IM cases in validation cohort 1. Age was compared using a two-sided Student's t-test. Sex and CSF findings were compared using a two-sided Fisher's exact test.

Validation Cohort 2	Anti-CD320 negative	Anti-CD320 positive	P-value
No. of patients (%)	13 (52)	12 (48)	
Age (range)	61 (34-76)	54 (31-76)	0.188
Sex (%)			0.999
Female	5 (38)	4 (33)	
Male	8 (62)	8 (67)	
MRI pattern (%)			0.431
Normal	2 (15)	1 (8)	
Dorsolateral	2 (15)	5 (42)	
Other	9 (70)	6 (50)	

Supplementary Table 6. Comparison of anti-CD320 negative and positive IM cases in validation cohort 2. Age was compared using a two-sided Student's t-test. Sex and MRI findings were compared using a two-sided Fisher's exact test.

¹ Larman, H. B. *et al.* Autoantigen discovery with a synthetic human peptidome. *Nat. Biotechnol.* **29**, 535–541 (2011).

² Mandel-Brehm, C. *et al.* Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis. *N. Engl. J. Med.* **381**, 47–54 (2019).

³ Vazquez, S. E. *et al.* Identification of novel, clinically correlated autoantigens in the monogenic autoimmune syndrome APS1 by proteome-wide PhIP-Seq. *Elife* **9**, (2020).

⁴ Vazquez SE, Mann SA, Bodansky A, et al. Autoantibody discovery across monogenic, acquired, and COVID-19-associated autoimmunity with scalable PhIP-seq. *Elife* [Internet] 2022;11. Available from: <http://dx.doi.org/10.7554/eLife.78550>